Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Stoke Therapeutics, Inc. (STOK) is anticipated to report a year-over-year increase in earnings driven by higher revenues, which could significantly influence its near-term stock price depending on the actual results compared to estimates [1][2]. Earnings Expectations - The upcoming earnings report is expected to show a quarterly loss of $0.51 per share, reflecting a year-over-year improvement of +15$3.88 million, representing a 38.6% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 1.85% lower in the last 30 days, indicating a reassessment by analysts [4]. - The Zacks Earnings ESP for Stoke Therapeutics is +1.48%, suggesting a positive outlook for the company's earnings prospects [10][11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [8]. - Stoke Therapeutics has a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Stoke Therapeutics was expected to post a loss of $0.52 per share but actually reported a loss of$0.47, resulting in a surprise of +9.62% [12]. - The company has successfully beaten consensus EPS estimates in the last four quarters [13]. Conclusion - While Stoke Therapeutics is positioned as a compelling earnings-beat candidate, other factors should also be considered when evaluating the stock ahead of its earnings release [16].